ORIC Pharmaceuticals, Inc. Form 8-K Summary
Reporting date: November 7, 2022. The filing reports the issuance of a press release covering financial results for the fiscal quarter ended September 30, 2022.
Business Context and Reporting Period
ORIC Pharmaceuticals, Inc. is a Delaware biotechnology company whose common stock trades on Nasdaq under the symbol ORIC. The filing is a current report under Sections 13 or 15(d) of the Exchange Act and identifies the third quarter of 2022 as the relevant reporting period.
Financial Results and Liquidity
The filing text provided does not include the attached press release’s financial data. Accordingly, revenue, net income or loss, operating expenses, cash flow, cash and cash equivalents, cash runway, debt, liquidity, and margins are not clearly stated.
Material Changes Versus Prior Period
The filing does not provide sufficient financial information to assess changes versus the comparable prior-year quarter or the immediately preceding quarter.
Guidance, Outlook, Risks, and Unusual Items
No guidance, outlook, management commentary, contingencies, or unusual items are described in the filing text provided. These matters may be addressed in Exhibit 99.1, the November 7, 2022 press release, which is referenced but not included in the supplied content.
Items 2.02 and 9.01, including the exhibit, were furnished and are not deemed filed for purposes of Section 18 of the Exchange Act or incorporated by reference into other filings except where expressly stated.
Investor Verification Items
- Obtain and review Exhibit 99.1 for the quarter’s reported financial results.
- Verify cash, cash equivalents, investments, operating cash burn, and projected liquidity runway.
- Review research and development expenses, general and administrative expenses, and net loss compared with prior periods.
- Check for updated clinical-development timelines, financing plans, partnership activity, and other forward-looking statements.
- Assess risk disclosures and any changes to the company’s pipeline or clinical programs.